Akero Therapeutics is a biotechnology company that focuses on the development of innovative therapies for the treatment of chronic metabolic diseases, particularly non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)
The company is dedicated to advancing its pipeline of pharmaceutical candidates, utilizing its proprietary technology and a deep understanding of liver disease mechanisms to address unmet medical needs. By conducting rigorous clinical trials and research, Akero aims to deliver effective treatment options that can improve patient outcomes and contribute to the overall health of individuals affected by these conditions.
Check out this week's top-performing mid-cap stocks, including Akero Therapeutics' remarkable 106.57% surge following positive clinical trial results and other companies like Surgery Partners experiencing significant growth due to strategic developments.
The analyst highlighted that major pharmaceutical companies are already pursuing GLP-1-based therapies for MASH, but he believes efruxifermin could complement these treatments.
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating on Eli Lilly with a price target of $885. Eli Lilly's Q2 FY24 earnings report on August 8 will include a pre-tax IPR&D charge of $154 million, impacting GAAP and non-GAAP EPS by $0.14.
Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress 2024. Phase 2 tirzepatide trial shows promising results for MASH treatment. Further trials needed to confirm efficacy and safety.
